- 2025.
- 2024.
- 2023.
- 2022.
- 2021.
- 2020.
- 2019.
- 2018.
- 2017.
- 2016.
- 2015.
- 2014.
- 2013.
- 2012.
- 2011.
- 2010.
- 2009.
- 2008.
- 2007.
- 2006.
- 2005.
- 2004.
- 2003.
- 2002.
- 2001.
- 2000.
- 1999.
- 1998.
- 2025.
- 2024.
- 2023.
- 2022.
- 2021.
- 2020.
- 2019.
- 2018.
- 2017.
- 2016.
- 2015.
- 2014.
- 2013.
- 2012.
- 2011.
- 2010.
- 2009.
- 2008.
- 2007.
- 2006.
- 2005.
- 2004.
- 2003.
- 2002.
- 2001.
- 2000.
- 1999.
- 1998.
2000.
-
- Nov.07.2000
- Ono and Schering-Plough Signed a License Agreement For Leukotriene Antagonist Pranlukast Hydrate(40 KB)
-
- Jun.26.2000
- Ono Enters Collaboration with CuraGen for Functional Genomic Technologies(46 KB)
-
- Jun.21.2000
- Ono and Lilly signed a License Agreement on the Worldwide Development and Marketing of a Novel Therapeutic Drugfor Acute Lung Injury(39 KB)
-
- Jun.19.2000
- Current regulatory NDA review status of ELASPOL® in Japan(51 KB)
-
- Apr.17.2000
- Ono and Lilly Agree to Collaborate on the Worldwide Development and Marketing of a Novel Therapeutic Drug for Acute Lung Injury(40 KB)
-
- Mar.06.2000
- Dividends distribution for the fiscal term ending March,2000 (the 52nd term)(45 KB)
-
- Jan.21.2000
- Additional Indication for 'Onon Capsule' (pranlukast hydrate)(38 KB)
-
- Jan.20.2000
- Ono Launches 'Onon Dry Syrup' (pranlukast hydrate)(38 KB)